Moderna's 3-month data raise hopes for COVID-19 vaccine durability

Antibody levels stayed elevated in the 90 days after people received the second dose of Moderna’s COVID-19 vaccine, raising hopes that the prophylactic can provide protection for one year.

With Moderna and Pfizer, in partnership with BioNTech, showing mRNA vaccines provide protection against symptomatic COVID-19 in the short term, attention has turned to durability. The full picture of the durability of protection will only become clear over time, but immunogenicity data from the phase 1/2 trial of Moderna’s mRNA-1273 offer encouragement.